PDT Partners’s Axsome Therapeutics AXSM Stock Holding History

PDT Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$355K	Sell	2,100 -1,477	-41%	-$255K	0.02%	450
2025 Q4	$653K	Buy	+3,577	New	+$499K	0.04%	387
2025 Q2	–	Sell	-51,199	Closed	-$5.97M	–	692
2025 Q1	$5.97M	Buy	51,199 +47,004	+1,120%	+$5.35M	0.42%	42
2024 Q4	$355K	Sell	4,195 -7,506	-64%	-$690K	0.03%	539
2024 Q3	$1.05M	Buy	+11,701	New	+$1.02M	0.09%	353
2022 Q4	–	Sell	-8,397	Closed	-$375K	–	642
2022 Q3	$375K	Sell	8,397 -59,270	-88%	-$2.96M	0.06%	521
2022 Q2	$2.59M	Buy	+67,667	New	+$2.14M	0.23%	117

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PDT Partners's AXSM Position: Q1 2026 in Review

PDT Partners reduced its Axsome Therapeutics (AXSM) stake by 41% in Q1 2026, selling an estimated $255K and leaving 2,100 shares worth $355K. The position accounts for 0.02% of the portfolio, ranked #450.

PDT Partners first reported a position in AXSM in Q2 2022 and has held it in 7 quarters since. The position peaked at $5.97M in Q1 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

PDT Partners held 2,100 shares of Axsome Therapeutics worth $355K as of Q1 2026.
PDT Partners sold 1,477 Axsome Therapeutics shares in Q1 2026, an estimated $255K.
Axsome Therapeutics made up 0.02% of PDT Partners's portfolio in Q1 2026, its #450 holding.
PDT Partners first reported a position in Axsome Therapeutics in Q2 2022 and has held it in 7 quarters since.
PDT Partners's Axsome Therapeutics position peaked at $5.97M in Q1 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.